<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121196">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02143271</url>
  </required_header>
  <id_info>
    <org_study_id>7580-004</org_study_id>
    <nct_id>NCT02143271</nct_id>
  </id_info>
  <brief_title>Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis</brief_title>
  <official_title>A Single-dose Phase 1 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Company, Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Company, Limited</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after
      single administration of KHK7580 for secondary hyperparathyroidism in patients receiving
      peritoneal dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number and types of adverse events</measure>
    <time_frame>For 8 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The safety of KHK7580 assessed by number and types of adverse events, laboratory tests, vital signs and electrocardiogram</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profiles of pharmacokinetics</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72 and 168 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>intact parathyroid hormone, whole parathyroid hormone, corrected serum calcium, phosphorus, intact fibroblast growth factor 23, ionized calcium, calcitonin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>KHK7580</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK7580</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>KHK7580</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Stable chronic renal disease patients receiving peritoneal dialysis for at least 16
             weeks prior to the screening

          -  intact parathyroid hormone value ≥ 240 pg/mL at the screening

          -  Corrected serum calcium ≥ 8.4 mg/dL at the screening

        Exclusion Criteria:

          -  Patients with primary hyperparathyroidism

          -  Patients who received cinacalcet within 2 weeks prior to the screening

          -  Patients who began to take or changed the dose/dosing regimen of active vitamin D/its
             analogs, phosphate binders and/or calcium containing compounds within 2 weeks prior
             to the screening

          -  Patients who underwent parathyroidectomy and/or parathyroid intervention

          -  Patients with uncontrolled hypertension and/or diabetes

          -  Patients with severe heart disorder

          -  Patients with severe hepatic disease

          -  Patients who take investigational drug in another clinical trial within 12 weeks
             prior to the screening

          -  Patients who have been judged ineligible to participate in the study by the
             investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyowa Hakko Kirin</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KYOWA HAKKO KIRIN</last_name>
      <email>clinical.info@kyowa-kirin.co.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>May 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
